Iain D. Milligan

Iain D. Milligan

Auto-generated profile, based on publicly available information

Iain D. Milligan

Directorate of Infection, Guy’s & St Thomas’ National Health Service Foundation Trust , London , UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2016 in JAMA
Verified
Journal Article
Closed access
PDF file
IMIain D. Milligan
Iain D. Milligan
MGMalick M. Gibani
Malick M. Gibani
RSRichard Sewell
Richard Sewell
ECElizabeth A. Clutterbuck
Elizabeth A. Clutterbuck
DCDanielle Campbell
Danielle Campbell
MSMatthew D. Snape
Matthew D. Snape
Research from JAMA — Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines — A Randomized Clinical Trial

7 December 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLuke B Snell
Luke B Snell
AMAimee McGreal-Bellone
Aimee McGreal-Bellone
CNClemency Nye
Clemency Nye
SGSarah Gage
Sarah Gage
PBPrijay Bakrania
Prijay Bakrania
GNGaia Nebbia
Gaia Nebbia
The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where persistent SARS-CoV-2 infection was successfully treated with prolonged courses (median, 10 days [range, 10–18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most cases (9/11) had hematological malignancy and 10 (10/11) had received CD20-depleting therapy. The median duration of infection was 103 days (interquartile range, 85–138 days). The majority (10/11) were hospitalized, and 7 (7/11) had severe/critical disease. All survived and 9 of 11 demonstrated viral clearance, almost half (4/9) of whom received nirmatrelvir/ritonavir as monotherapy. This case series suggests that prolonged nirmatrelvir/ritonavir has a role in treating persistent infection.